A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own LUNG shares is 170, representing N/A of the company's common stock.

MORGAN STANLEY, in the last quarter, reduced its stake in LUNG by -12.88% restricting it's holding to 1.85 Million shares of worth nearly $30.89 Million. BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. also lessened -0.09% of the LUNG shares from its portfolio, reducing its holding to 922.53 Thousands shares of worth $15.37 Million. N/A also shunned LUNG shares holding by N/A last quarter which brought its holding to 0 shares worth $0.

As per its latest 13F filing, PRIMECAP MANAGEMENT CO/CA/ increased its stake in LUNG by 0.65% in the last quarter. The institutional holder raised its holding to 5.43 Million shares having worth more than $90.51 Million. DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) also added 7.36% more shares of LUNG to its portfolio, raising its holding to 3.72 Million shares of worth $61.99 Million. VANGUARD GROUP INC also increased its LUNG shares holding by 0.58% which brought its holding to 3.15 Million shares worth $52.51 Million.

The insider with the most stakes in LUNG is BOSTON SCIENTIFIC CORP , a 10 percent owner at the company. Additionally, LUNG stock is highly held by President and CEO FRENCH GLENDON E. III and Chief Financial Officer SUNG DERRICK among others.

Company executives, directors, and other insiders own 4.2 percent of Pulmonx Corporation's stock. Within the last six months, there have been 16 transaction(s) in which LUNG insiders have sold stock, totaling 13,453 shares. Insiders that have sold shares include ROSE GEOFFREY BERAN, LEHMAN DAVID AARON, and FRENCH GLENDON E. III.

There have been 3 transaction(s) during the past 6-months in which LUNG insiders have bought stock , totaling $7,138 FERRARI RICHARD., LYNCH ALISSA HSU.

Around 1.57 Million Pulmonx Corporation shares are held by insiders, which represents about 4.20% of LUNG Stock.

LUNG 10 percent owner, BOSTON SCIENTIFIC CORP holds the largest portfolio of the company's shares. LUNG shares owned by Levinson total nearly 1.49 Million.

PRIMECAP MANAGEMENT CO/CA/ is the largest institutional owner in LUNG which holds 5.43 Million shares worth $90.51 Million or 14.68% of the total LUNG shares outstanding followed by DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) with ownership of 3.72 Million shares representing 10.06% of the LUNG ownership. VANGUARD GROUP INC, Inc is the third largest stakeholder with 3.15 Million shares or 8.52% of the ownership worth more than $52.51 Million.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the LUNG is concerned, it is a stock which is optionable.

Number of LUNG shares short as of 2023-01-12 was 2.95 Million. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 37.38 Million shares of LUNG are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, LUNG has 36.03 Million shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for LUNG was N/A as of 2023-01-12.